Organ‐on‐a‐Chip: A Preclinical Microfluidic Platform for the Progress of Nanomedicine
-
- Raquel O. Rodrigues
- Center for MicroElectromechanical Systems (CMEMS‐UMinho) University of Minho Campus de Azurém Guimarães 4800‐058 Portugal
-
- Patrícia C. Sousa
- Microfabrication and Exploratory Nanotechnology INL–International Iberian Nanotechnology Laboratory Av. Mestre José Veiga Braga 4715‐330 Portugal
-
- João Gaspar
- Microfabrication and Exploratory Nanotechnology INL–International Iberian Nanotechnology Laboratory Av. Mestre José Veiga Braga 4715‐330 Portugal
-
- Manuel Bañobre‐López
- Advanced (magnetic) Theranostic Nanostructures Lab Nanomedicine Unit INL–International Iberian Nanotechnology Laboratory Av. Mestre José Veiga Braga 4715‐330 Portugal
-
- Rui Lima
- Transport Phenomena Research Center (CEFT) Faculdade de Engenharia da Universidade do Porto (FEUP) R. Dr. Roberto Frias Porto 4200–465 Portugal
-
- Graça Minas
- Center for MicroElectromechanical Systems (CMEMS‐UMinho) University of Minho Campus de Azurém Guimarães 4800‐058 Portugal
説明
<jats:title>Abstract</jats:title><jats:p>Despite the progress achieved in nanomedicine during the last decade, the translation of new nanotechnology‐based therapeutic systems into clinical applications has been slow, especially due to the lack of robust preclinical tissue culture platforms able to mimic the in vivo conditions found in the human body and to predict the performance and biotoxicity of the developed nanomaterials. Organ‐on‐a‐chip (OoC) platforms are novel microfluidic tools that mimic complex human organ functions at the microscale level. These integrated microfluidic networks, with 3D tissue engineered models, have been shown high potential to reduce the discrepancies between the results derived from preclinical and clinical trials. However, there are many challenges that still need to be addressed, such as the integration of biosensor modules for long‐time monitoring of different physicochemical and biochemical parameters. In this review, recent advances on OoC platforms, particularly on the preclinical validation of nanomaterials designed for cancer, as well as the current challenges and possible future directions for an end‐use perspective are discussed.</jats:p>
収録刊行物
-
- Small
-
Small 16 (51), 2003517-, 2020-11-25
Wiley